FY20 ANNUAL GENERAL MEETING ANNUAL GENERAL MEETING

Full text

(1)

FY20 ANNUAL GENERAL MEETING

(2)

DISCLAIMER

This presentation and any Materials provided (materials) have been prepared by Fiji Kava Limited (Fiji Kava) and contain general information about Fiji Kava activities. By accepting the Materials and attending the Fiji Kava presentation, you agree to be bound by the below terms and conditions.

Terms and Conditions

This presentation is provided for information purposes only. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision.

Certain statements in this presentation may constitute forward looking statements. Such statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

While all reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsidiaries, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on the

presentation by any person.

(3)

FIJI KAVA [ASX:FIJ]

“FIJI KAVA’S CLEAR AND CONSTANT

STRATEGY HAS HELPED US STAY ON

COURSE THROUGH THIS TURBULENT YEAR”

Andrew Kelly - Chair

(4)

COMPANY HIGHLIGHTS

Market Capitalization High of ~$32m

Appointment of Mr Jack Lowenstein to the Board of Fiji Kava as a Non-Executive Director.

Highest value-gain of any botanical stock on the ASX for Q1 FY21 at 160.3% and 91.9% versus last year 1

Successful completion of $4.8m (before costs) share placement at $0.18 per share to institutional, professional and sophisticated investors

Evolving nature of Coronavirus and its impact on the macro environment both domestically & internationally

Mr Nicholas Simms was appointed as Chief Executive Officer on an interim basis on 19 October 2020

KEY MILESTONES

$764k

REVENUE FY20

+

320%

VERSUS PCP : FY19

Please refer to Appendix for reference

$4.2m

CASH BALANCE

$

17.3m

(5)

FY20 REVENUE GREW 320% VERSUS THE PRIOR CORRESPONDING PERIOD,

DEMONSTRATING LUMPY BUT STEADY REVENUE GROWTH

$0 $100 $200 $300 $400 $500 $600 $700 $800 FY19 FY20

$ REVENUE 000’s

H1 H2 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% H1 H2

% PRODUCT MIX

Industrial Powder Capsules

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% H1 H2

% MARKETS

(6)

GROWING

GLOBAL

(7)

OVER $270 BILLION SPENT ON CONSUMER HEALTH GLOBALLY IN 2020

& FORECAST TO GROW AT 2.1% YOY to 2025

10

The global market for ‘Sleep Aid’ supplements is worth $3.7B in 2020 and is expected to grow YOY at 9.3% to 2025 2

Global Insomnia Market estimated to reach $5.5 billion by 2023 3 Over 60% of the population in developed nations suffer from stress and anxiety related issues 4

Anxiety Market Size – USD $15.60 Billion in 2018 and forecast to grow at CAGR of 2.4% 5

The global Pain Management Market estimated at $61.05 billion in 2017 and is projected to grow to $77.13 billion by 2023 6 Over half of Australians experience one of Sleeplessness,

Calmness or Sore Muscles need-states once per week or higher 7

(8)

3,000 YEARS AGO, IN THE MIDDLE OF THE PACIFIC

OCEAN. A BOTANICAL MARVEL WAS FOUND.

(9)

NOBLE KAVA SUPPLY

CHAIN EXCELLENCE

GROWING AVAILABILITY

OF FIJIAN NOBLE KAVA

INNOVATION & PRODUCT

DEVELOPMENT

MEDICINAL

BENEFITS

FIJI KAVA [ASX:FIJ]

MEDICINAL KAVA HEALTH & WELLNESS

COMPANY WHICH PRODUCES NATURAL

‘NOBLE KAVA’ PRODUCTS FOR THE

(10)
(11)

FIJI KAVA VERTICAL INTEGRATED SUPPLY

CHAIN PROVIDES UNPARRALLED TRUST &

TRANSPARENCY FOR CUSTOMERS

Fiji Kava only grow cultivars are of Noble variety, a superior form of Kava

Estate and tissue culture laboratory provides standardisation of Noble Kava varieties, which have the desirable kavalactone profiles for medicinal benefits

Pacific Horticultural and Agricultural Market Access Plus (PHAMA Plus) Program enables high-quality, sustainable nursery production of Fijian Noble Kava.

Regional Kava standard by the Codex Alimentarius Commission, has been adopted with the support of the United Nations and World Health Organisation (WHO).

Fiji Kava’s proprietary hydro extraction process is HACCP certified and compliant with Codex standards, including that Kava products be exclusively of the Noble Kava variety and developed to Food Safety Standards.

(12)
(13)

NEW FORMATS PROVIDING CONSUMERS WITH SAFE

NATURAL TREATMENTS FOR SLEEP, ANXIETY &

MUSCLE RELAXATION RELATED ISSUES

'Sleep', 'Mind’ & 'Body’ innovation strategy, including:

NEW Fiji Kava ‘Noble Calm’ vegan hard capsules combining Fiji Kava’s Noble Kava and Rhodiola rosea to calm the nerves, help relax the mind and support nervous system health to support general health and wellbeing

NEW Fiji Kava ‘Noble Sleep’ vegan hard capsules combining Fiji Kava’s Noble Kava and Jujube to induce sleep, relieve sleeplessness and support general health and wellbeing

NEW Fiji Kava ‘Noble Body’ vegan hard capsules combining Fiji Kava’s Noble Kava and Viburnum to enhance body relaxation, relieve muscle cramps and to support general health and wellbeing

Introduction of on pack provenance QR code to enable trust & transparency in Fiji Kava’s products and vertically integrated source of Noble Kava

New product development pipeline including innovation such as dietary shots 8& functional teas 8

(14)
(15)

AVAILABILITY AT COLES, LICENSE AGREEMENT

WITH BIOCEUTICALS AND STRONG PARTNER

SECURED FOR CHINA

Yuan Long Yato Memorandum of Understanding to explore the marketing & distribution of Fiji Kava products to Chinese online platforms & direct networks PuMate (Shanghai) Limited partnership to enter the Chinese complementary medicine and cross-border e-commerce marketplaces.

License agreement with Blackmores owned BioCeuticals, to use of Fiji Kava's Noble Kava extracts in its Practitioner Clinical AnxioCalm product.

Continued focus on the development of Fiji Kava's 'Specialty Ingredients’ channel, promoting the sale of high-quality Noble Kava extracts.

Fiji Kava’s Noble Kava Extract capsules & NEW Noble Sleep, Noble Calm & Noble Body varieties in Coles Supermarkets and Coles Online.

Fiji Kava Noble Kava Extract & Noble Kava Root Powder products in Green Cross NZ [NZX:GXH] Unichem & Life Pharmacy outlets in NZ

(16)
(17)

FIJI KAVA CONTINUES TO BUILD AWARENESS

OF THE BENEFITS AS A SAFE NATURAL

ALTERNATIVE TO MEDICATIONS

NEW look packing ‘Noble Sleep’, ‘Noble Calm’ & ‘Noble Body’

Fiji Kava's Chief Scientific Advisor, Professor Jerome Sarris, continued work with the National Institute of Complementary Medicines (NICM) on clinical trial designs for innovative Kava delivery and dose formats.

Refreshed social media strategy, which has delivered over 1.6 million impressions and 210% increase in consumer engagement during the prior period 9

(18)

BEFORE USING FIJI KAVA NOBLE CALM I HAD CRIPPLING SOCIAL ANXIETY

SYMPTOMS, WITH AN UNCOMFORTABLE "ANXIETY CHATTER" IN MY HEAD

24/7 CAUSING ME TO MAKE EXCUSES NOT TO HANG OUT WITH FRIENDS,

CAUSE ISSUES SLEEPING AND OVERALL IMPAIRING MY QUALITY OF LIFE.

NOBLE CALM SIGNIFICANTLY REDUCED THAT ANXIETY CHATTER TO THE

POINT WHERE I AM NOW WANTING TO LEAVE THE HOUSE AND ENGAGE IN

SOCIAL EVENTS VOLUNTARILY AGAIN - I CAN NOT THANK THE FIJI KAVA

TEAM ENOUGH FOR THIS INCREASE IN QUALITY OF LIFE””

(19)

Fiji Kava’s value proposition is unique with its integrated supply chain, value added processing and branded focuses

Growing global complementary & alternative medicine market continues to grow driven by growing health and social concerns

Sleep, Anxiety & Muscle Relaxation Related Issues are growing social concerns globally in a $270 billion consumer health market globally 10 Fiji Kava continues to build pipeline of innovative new products to provide consumers with natural treatments for Sleep, Anxiety & Muscle Relaxation related issues

Focus on gaining distribution into key markets through building specialty ingredients & retail engagement and partnerships

Continue to build organizational capability & awareness of the benefits of Fiji Kava’s Noble Kava Extract & value-added products

DESPITE CURRENT MACRO

ENVIROMENTS, FIJI KAVA IS WELL

POSITIONED FOR LONG TERM

STRATEGIC GROWTH

(20)
(21)

APPENDIX

ASX www.asx.com.au : 27 November 2020 1 Bioshares Edition 863, 5thOctober 2020

2 Euromonitor Global Sleep Aids Analysis Nov 2020 3 www.alliedmarketresearch.com/insomnia-market 4 Euromonitor Global Health Report Oct 2020

5 Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs,

Benzodiazepines, Devices And Therapy, TMS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 – 2025. Kava Report 2003: In-Depth Investigation into EU Member States Market Restrictions on Kava Products

6

https://www.globenewswire.com/news-release/2019/05/13/1822497/0/en/Global-Pain-Management-Drugs-Market-to-Reach-77-13-Billion-by-2023-at-4-CAGR-Says-Allied-Market-Research.html

7 Fiji Kava Pillars and Demographics Research Project Nov 2020 (n=2,007). SQ1. How often do you experience issues / troubles

with ‘need state pillar’?

8 Market availability based on regulatory approval 9 Fiji Kava Social Media Performance Reporting

Figure

Updating...

References

Updating...

Related subjects :